Snapshot from Aug 24, 2026 at 07:00 UTC. For live data and tracking: View Live
Entities / Companies / Epidarex Capital
Entity

Epidarex Capital

Tracked across 2 events · 13 articles · First seen Jul 16, 2026 · Last active Aug 07, 2026

Sentiment
30
Attention
2
Events
2
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
Events (2)
2 50
Business
Mironid raises $46M Series B
Mironid, a Glasgow-based biopharmaceutical company developing small molecule therapeutics for Autosomal Dominant Polycystic Kidney Disease (ADPKD), announced on August 5, 2026 that it raised $46 million in a Series B funding round. The round was…
Impact: Epidarex Capital, an existing investor, contributed to the Series B, continuing its support for Mironid's development.
Aug 05, 2026 · 7 articles
2 10
Business
RapidPulse $48M Series B Financing
Impact: Existing investor Epidarex Capital participated.
Jul 16, 2026 · 6 articles
Key Actions (1)
70 Epidarex Capital invested MironidMironid raises $46M Series B
ERGEN INTELLIGENCE
Track Epidarex Capital live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.